U.S. Stock News

NYSE:NVR
NYSE:NVRConsumer Durables

Will Lower Q2 Earnings and a Major Buyback Change NVR's (NVR) Capital Allocation Narrative?

NVR, Inc. recently reported second-quarter 2026 results showing net income of US$236.46 million and diluted earnings per share of US$83.96, both lower than a year earlier. Alongside this earnings decline, NVR completed a previously announced buyback of 67,331 shares for US$442.25 million while not utilizing its newer May 2026 authorization. With earnings under pressure and a sizable buyback completed, we’ll examine how the profit decline reshapes NVR’s broader investment narrative. AI is...
NYSE:DE
NYSE:DEMachinery

Deere (DE) Rises Ahead Of Earnings But Is Its Valuation Already Priced In

Deere (DE) is back in focus after its stock rose 2.97% on the latest trading day, with investors looking ahead to the company’s August 20 earnings report and updated profit picture. See our latest analysis for Deere. At a share price of $628.16, Deere has built a strong run, with a 1 day share price return of 2.97% and a year to date share price return of 34.57%, while a five year total shareholder return of 85.52% underlines how the stock has rewarded patient holders. If Deere’s move has you...
NYSE:CHD
NYSE:CHDHousehold Products

How Signs Of Another Earnings Beat Amid Declines At Church & Dwight (CHD) Have Changed Its Investment Story

Church & Dwight is set to report its June 2026 quarter results on July 31, with analysts expecting earnings and revenue to be lower than a year earlier but still potentially ahead of consensus forecasts based on a positive Earnings ESP and recent estimate revisions. Analysts also highlight that Church & Dwight has exceeded consensus EPS estimates in each of the last four quarters, which is contributing to heightened investor attention around this upcoming announcement. With analysts flagging...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

NovoCure (NVCR) Is Up 10.9% After Raising 2026 Revenue Outlook and Securing New CE Mark Approval – Has The Bull Case Changed?

NovoCure recently reported its strongest-ever second quarter, with net revenue rising to US$183.58 million, a smaller net loss of US$15.66 million, and an upgraded 2026 net revenue outlook to US$710 million–US$725 million. The company also secured a CE Mark for its Optune Pax device in locally advanced pancreatic cancer and is anticipating FDA premarket approval for TTFields in brain metastases from non-small cell lung cancer, underscoring how expanding indications could reshape its...
NasdaqGS:BANF
NasdaqGS:BANFBanks

What BancFirst (BANF)'s Stronger Q2 Profit and Lower Charge-Offs Mean For Shareholders

BancFirst Corporation recently reported its second-quarter 2026 results, with net income rising to US$66.69 million and diluted earnings per share from continuing operations increasing to US$1.96, while net charge-offs declined to US$2.4 million from US$4.7 million a year earlier. This combination of higher profitability and lower credit losses suggests BancFirst’s loan portfolio performance has improved compared with the same period last year. We’ll now examine how BancFirst’s higher...
NYSE:CC
NYSE:CCChemicals

Is Broker Upgrades And Zacks Rank #1 Status Altering The Investment Case For Chemours (CC)?

Recently, brokers have upgraded their ratings on The Chemours Company, which now carries a Zacks Rank #1, backed by forecasts for stronger earnings growth into 2026. This shift in analyst sentiment highlights growing confidence in Chemours’ earnings outlook, potentially influencing how investors judge its longer-term profit recovery story. Next, we’ll examine how this uptick in broker ratings could reshape Chemours’ investment narrative around earnings quality and future growth. The latest...
NYSE:CL
NYSE:CLHousehold Products

Colgate-Palmolive (CL) Draws Q2 Attention, Is The Valuation Already Priced In?

Q2 Earnings Anticipation and Dividend Move Put Colgate-Palmolive in Focus Colgate-Palmolive (CL) is in the spotlight as investors look ahead to Q2 results, with attention on international performance, organic sales trends, and a higher quarterly dividend of US$0.53 per share. See our latest analysis for Colgate-Palmolive. At a share price of US$90.75, Colgate-Palmolive has had a mixed near term patch, with the share price return declining 2.4% over the past week but rising 7.8% over 90 days...
NYSE:THC
NYSE:THCHealthcare

Tenet Healthcare (THC) Raised Full Year Guidance, Does It Look Fairly Valued?

Tenet Healthcare (THC) is back on investors' radar after second quarter 2026 earnings and new full year guidance pointed to stronger profitability, higher revenue expectations and a larger share repurchase program. See our latest analysis for Tenet Healthcare. The latest earnings and guidance reset have clearly shifted sentiment, with Tenet Healthcare’s share price up 17.17% on the day and posting a 25.69% 3 month share price return. The 1 year total shareholder return of 52.40% and 3 year...
NYSE:EW
NYSE:EWMedical Equipment

Edwards Lifesciences (EW) Stock Looks Rich Despite Near Fair Value

Edwards Lifesciences stock sits in an interesting spot for investors right now, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the current price is roughly in line with fair value, while the broader valuation checks and recent 5 year share price record do not point to a clear bargain. Over the past 5 years, Edwards Lifesciences shares have declined 26.4%, which puts more focus on whether today’s price now fairly reflects the company’s prospects. Recent optimism...
NYSE:TRU
NYSE:TRUProfessional Services

TransUnion (TRU) On New Mortgage Data Push Is The Stock A Bargain Or Fairly Priced

TransUnion (TRU) has drawn fresh attention after introducing TruVision Alternative Credit Attributes (ACA 2.0) into its mortgage credit reports. The company is using FactorTrust data to broaden lender insight beyond traditional credit files and earlier in the loan funnel. See our latest analysis for TransUnion. Against this product update backdrop, TransUnion's share price has moved to $76.51, with a 30 day share price return of 8.76% and a 90 day gain of 7.47%. However, the 1 year total...
NYSE:SCHW
NYSE:SCHWCapital Markets

Charles Schwab (SCHW) Following Strong Q2 Earnings Through A Valuation Lens

Why Charles Schwab Stock Is Back in Focus After Q2 Results Charles Schwab (SCHW) is drawing attention after reporting second quarter net income of US$2.8b and basic earnings per share of US$1.55, both higher than the figures reported a year earlier. See our latest analysis for Charles Schwab. Alongside the stronger Q2 and first half results and fresh dividend declarations, Charles Schwab’s share price has climbed to US$101.97, with a 30 day share price return of 12.46% and a 1 year total...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Does Stoke Therapeutics’ New Genetic Medicine CSO Hire Reframe Its R&D Ambitions for STOK?

Earlier this month, Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, adding more than 25 years of R&D and rare disease drug development leadership to its senior team. His background in advancing genetic and RNA-based medicines, including experience with mRNA technologies and antisense platforms, could be particularly relevant to Stoke’s antisense oligonucleotide programs targeting severe genetic diseases. Next, we’ll examine how bringing in a Chief Scientific...
NYSE:BLSH
NYSE:BLSHCapital Markets

Bullish Stock And 2 Market Infrastructure Plays Worth A Closer Look

Energy and commodity market infrastructure stocks are back in focus after fresh data on Intercontinental Exchange, or ICE, highlighted how quickly sentiment around trading venues and data providers can shift. Record open interest in ICE natural gas and power contracts has sharpened attention on where future cash flows might come from, while a P/E of 21.0x against a 16.8x fair value estimate and a share price about 6.3% above an intrinsic value estimate of US$137.18 underline valuation...
NYSE:C
NYSE:CBanks

Citigroup (C) Stock Still Looks Reasonable Even After A 208% Run

Citigroup stock has logged a very large 207.6% return over the past three years, yet current checks suggest it still trades at a discount, with both the Excess Returns intrinsic value estimate and earnings multiples pointing to an undervalued profile rather than a stretched one. Over the past three years, Citigroup has delivered a 207.6% return, which puts the current share price in focus against what the underlying value signals suggest. Recent progress on Citi's multi year transformation,...
NYSE:BYD
NYSE:BYDHospitality

Is Boyd Gaming’s Higher Online Guidance Offsetting Softer Q2 Profit Trends For BYD?

Boyd Gaming reported past second-quarter 2026 results showing sales of US$733.7 million and revenue of US$1.03 billion, with net income easing to US$131.23 million and diluted EPS from continuing operations at US$1.75. Despite flat overall revenue and lower net income, Boyd Gaming highlighted growth in its Midwest and South operations, continued share repurchases and dividends above US$170 million, and raised guidance for its Online and Managed businesses. Now we’ll examine how Boyd Gaming’s...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

Will SEI’s Q2 Revenue Gain, Profit Dip and Completed Buyback Shift SEI Investments’ (SEIC) Narrative?

In the second quarter of 2026, SEI Investments reported higher revenue of US$641.62 million but lower net income of US$195.66 million year-on-year, while also completing a US$6.13 billion share repurchase program first announced in 2005. SEI also expanded its product lineup by launching the SEI QiM U.S. Equity Factor Allocation Active ETF, giving investors access to its quantitative factor research through a transparent, tax-efficient vehicle. We’ll now examine how SEI’s strong revenue...